Focus: HistoSonics is a publicly-traded medical device biotech specializing in non-invasive, autonomous robotic platforms using histotripsy technology for oncology and urological indications. The company is in early-stage clinical development with a lean, focused pipeline centered on the Edison™ system.
Profile data last refreshed 5h ago · AI intelligence enriched 2mo ago
Best suited for early-stage biotech enthusiasts comfortable with device development uncertainty and seeking exposure to proprietary platform technology with multi-indication potential.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for HistoSonics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from HistoSonics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
HistoSonics Secures Taiwan Approval For Edison Histotripsy System - BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System - BioPharma APAC
HistoSonics Secures Taiwan Approval For Edison Histotripsy System BioPharma APAC
HistoSonics seeks FDA authorization to expand focused ultrasound system to kidney tumors - Medical Economics
HistoSonics seeks FDA authorization to expand focused ultrasound system to kidney tumors Medical Economics
The 10 Most Influential Health and Life Science Companies of 2026 - Time Magazine
The 10 Most Influential Health and Life Science Companies of 2026 Time Magazine
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH) - BioSpace
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH) BioSpace
Samsung Medison expands into ultrasound therapy through HistoSonics partnership - koreabiomed.com
Samsung Medison expands into ultrasound therapy through HistoSonics partnership koreabiomed.com
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo